Alert: Australia Relaxes Psychedelics Access; U.S. Federal Lobbying Active

Australia has eased its psychedelics access regulations, potentially creating new market and research opportunities for regulated substances. In the U.S., Q1 2026 federal lobbying data reveals ongoing efforts to shape psychedelic policy, while new MDMA therapy trials are launching in Maryland and via the VA. Merchants should closely monitor these international and domestic developments for emerging compliance requirements and market shifts.

Key compliance and access developments:

Q1 2026 Federal Psychedelic Lobbying Update reveals ongoing legislative advocacy in the U.S.
Australia Loosens Psychedelics Access Pathway Regulations, indicating a shift in international market access.
State of Maryland and Reason for Hope Fund Sunstone Study to Compare Group vs. Individual MDMA-Assisted Therapy for PTSD.
VA Launches “New” MDMA Trial, with the first announcement in December 2024, expanding therapeutic research.

Sentinel Insight